As organizations representing the rare disease community, we are very concerned about Independence Blue Cross Blue Shield’s (IBX) policy (08.02.35) that excludes coverage for FDA-approved rare disease...

The impact of Medicare’s price negotiation on long-term pharmaceutical innovation and patient welfare remains one of the most widely debated topics across stakeholder groups. Existing policy simulatio...

Biomedical innovators are developing new autoimmune therapeutics - insurance reform will ensure new treatments and cures are accessible and affordable.

Patients who contest denials face a daunting process, but many are successful. “This appeal saved my life.”